Granular preparation

LAP672AUndetermined Publication Date: 2025-12-19EA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP672
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-02-21
Filing Date
2018-02-20
Publication Date
2025-12-19

AI Technical Summary

Technical Problem

Current granule formulations containing isoleucine, leucine, and valine for treating liver diseases, such as hypoalbuminemia in decompensated liver cirrhosis, suffer from unpleasant bitterness and lingering taste, which detract from the patient experience.

Method used

Incorporating a gelling agent, specifically carboxyvinyl polymer or polyethylene oxide, into the granule formulation to improve the administration feel, with the gelling agent being added as a powder and present in a concentration of 0.05 to 2% based on the total granule preparation, enhancing the granule's gelation properties and mouthfeel.

Benefits of technology

The addition of a gelling agent significantly improves the taste and swallowing experience of the granules, reducing bitterness and lingering sensations, while maintaining the medicinal efficacy and dissolution properties of the active ingredients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a granular preparation having improved unpalatabiJ-ity and containing isoleucine, leucine and valine. The present invention relates to a granular preparatj.on containing isoleucine, leucine and val-ine as active ingredients and containing a gelling agent.
Need to check novelty before this filing date? Find Prior Art

Description

Granule formulation

[0001] The present invention relates to a granule formulation. Specifically, the present invention relates to a granule formulation containing isoleucine, leucine, and valine.

[0002] As a pharmaceutical containing isoleucine, leucine, and valine, Livact (registered trademark, hereinafter the same) compound granules, which is an effective therapeutic agent for liver diseases, etc. Livact compound granules contain 4 g of the active ingredient in one packet (4.15 g) and are used to improve hypoalbuminemia in patients with decompensated liver cirrhosis who exhibit hypoalbuminemia despite sufficient dietary intake (Non-Patent Document 1).

[0003] Package insert: Branched-chain amino acid preparations, Japanese Pharmacopoeia, isoleucine, leucine, valine granules, Livact (registered trademark) combined granules, revised April 2016 (17th edition)

[0004] Livact Granules is a granule formulation containing a large amount of amino acid components, so there is a need for further improvement in the swallowing experience, such as the bitter taste derived from amino acids and the lingering feeling of the granules in the mouth.

[0005] An object of the present invention is to provide a granule preparation containing isoleucine, leucine and valine that has an improved feeling when taken.

[0006] As a result of extensive research, the present inventors have discovered that the above-mentioned problems can be solved by adding a gelling agent to a granule preparation containing isoleucine, leucine, and valine, and have completed the present invention.

[0007] That is, the present invention is as follows: (1) A granule preparation containing isoleucine, leucine, and valine as active ingredients, which further contains a gelling agent. (2) The granule preparation according to (1), wherein the gelling agent is a carboxyvinyl polymer or polyethylene oxide. (3) The granule preparation according to (1) or (2), wherein the gelling agent is polyethylene oxide having an average molecular weight of 500,000 or more. (4) The granule preparation according to any one of (1) to (3), wherein the gelling agent is added as a powder. (5) The granule preparation according to any one of (1) to (4), wherein the gelling agent is contained in an amount of 0.05 to 2% based on the total amount of the granule preparation. (6) The granule preparation according to any one of (1) to (5), wherein the gelling agent is contained in a weight ratio of isoleucine / leucine / valine = 1 / 1.9 to 2.2 / 1.1 to 1.3. (7) A granule formulation according to any one of (1) to (6), containing 80% or more of isoleucine, leucine, and valine relative to the total amount of the granule formulation. (8) A granule formulation according to any one of (1) to (7), further containing a binder and / or a flavoring agent. (9) A method for producing a granule formulation containing isoleucine, leucine, and valine as active ingredients, comprising adding a gelling agent to granules containing isoleucine, leucine, and valine. (10) The production method according to (9), wherein a gelling agent is added in powder form.

[0008] According to the present invention, a granule preparation containing isoleucine, leucine and valine having an improved feeling when taken can be provided.

[0009] 1 shows the results of a dissolution test of the granule formulation of Example 1. FIG. 2 shows the results of a dissolution test of the granule formulation of Comparative Example 1.

[0010] The present invention will be specifically described with reference to the following embodiments, but the present invention is not limited to the following embodiments and can be implemented in various modified forms.

[0011] The granule formulation of the present invention contains isoleucine, leucine, and valine as active ingredients and a gelling agent. The isoleucine, leucine, and valine used as active ingredients in the granule formulation of the present invention are amino acids known as branched-chain amino acids. In the present invention, the D- and L-isomers may be used, or a mixture of the D- and L-isomers in any ratio may be used, or the DL-isomer may be used. Isoleucine, leucine, and valine may each be chemically synthesized or fermented. It is preferable to use L-isoleucine, L-leucine, and L-valine that meet the specifications set forth in the 17th edition of the Japanese Pharmacopoeia (pages 483, 1711-1712, and 1248, respectively).

[0012] In the present invention, "containing isoleucine, leucine, and valine as active ingredients" means that the granule formulation of the present invention contains isoleucine, leucine, and valine as ingredients that exert efficacy when used as a pharmaceutical. In Japan, the efficacy of pharmaceuticals containing isoleucine, leucine, and valine as active ingredients is known to be "improvement of hypoalbuminemia in patients with decompensated cirrhosis who exhibit hypoalbuminemia despite sufficient dietary intake," as observed with the commercially available Livact Granules. However, the efficacy of the granule formulation of the present invention containing isoleucine, leucine, and valine as active ingredients is not limited to this efficacy. While other active ingredients may be included in the present invention, it is preferred that the granule formulation of the present invention contain only isoleucine, leucine, and valine. By including isoleucine, leucine, and valine as active ingredients, the granule formulation of the present invention can be used as a pharmaceutical granule formulation.

[0013] In the granule formulation of the present invention, the content ratio of isoleucine, leucine, and valine is not particularly limited, but is preferably isoleucine / leucine / valine = 1 / 1.9 to 2.2 / 1.1 to 1.3 by weight. The contents of isoleucine, leucine, and valine are set appropriately, but the lower limit of their content, expressed as a mass percentage relative to the total amount of the granule formulation, is preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more. The upper limits of the contents of isoleucine, leucine, and valine are not particularly limited, but the contents of isoleucine, leucine, and valine are preferably less than 100%, more preferably 99% or less, even more preferably 98% or less, and even more preferably 97% or less. The contents of isoleucine, leucine, and valine may be within a range combining the values ​​described as preferred upper and lower limits.

[0014] The granule formulation of the present invention contains a gelling agent. In the present invention, a gelling agent refers to a formulation additive that is a base material that gels when it contains water. Examples of gelling agents include, but are not limited to, hypromellose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, sodium alginate, carrageenan, xanthan gum, tamarind gum, pectin, locust bean gum, gellan gum, agar, and polyethylene oxide. From the viewpoints of gelling ability and gelling rate, carboxyvinyl polymer and polyethylene oxide are preferred, and polyethylene oxide is more preferred. The gelling agent may be used alone or as a mixture of two or more types.

[0015] The average molecular weight of the gelling agent is appropriately set depending on the type of gelling agent, taking into consideration indicators such as gelling ability and gelling rate. Gelling ability can be confirmed, for example, by observing the appearance of the gelling agent when dissolved in water at high and low concentrations. The gelling rate can be confirmed by adding and dissolving the gelling agent in water, stirring, and observing the gelation state over time. Concentrations for measuring gelling ability include, for example, high concentration (10 w / v%) and low concentration (1 w / v%), and concentrations for measuring gelling rate include, for example, 10 w / v%.

[0016] The lower limit of the average molecular weight of polyethylene oxide is preferably 150,000 or more, more preferably 500,000 or more, even more preferably 1,000,000 or more, and even more preferably 2,000,000 or more. The upper limit of the average molecular weight of polyethylene oxide is not particularly limited, but the average molecular weight of polyethylene oxide is preferably 10,000,000 or less, and more preferably 5,000,000 or less. The average molecular weight of polyethylene oxide may be within a range that combines the values ​​described as preferred upper and lower limits.

[0017] In the present invention, the average molecular weight of the gelling agent may be the value indicated on the product, but it can also be measured as the viscosity average molecular weight by measuring the viscosity of a solution of the gelling agent.

[0018] The gelling agent contained in the granule formulation of the present invention is preferably present in the form of a powder. The powder addition of the gelling agent is carried out on elementary granules containing isoleucine, leucine, and valine. By adding the gelling agent as a powder to the elementary granules, the gelling agent is present on the surface of the granules in the form of a powder addition.

[0019] When a gelling agent is added as a powder to a granule formulation of the present invention, the gelling agent is present on the surface of the granules in a powdered state. Therefore, the granule formulation of the present invention differs from so-called coated granules (coated granules) in which the gelling agent is coated on the surface of the granules. In coated granules, elementary granules containing isoleucine, leucine, and valine are coated with a coating liquid. In this case, the gelling agent is contained in the coating liquid. The presence of a gelling agent in a powdered form in a granule formulation can be confirmed, for example, by evaluating the gelling ability of the powder obtained by separating the granules by sieving, without particular limitation. The presence of a gelling agent in a powdered form can also be confirmed by spectroscopic image observation, for example.

[0020] The content of the gelling agent is appropriately determined depending on the type of gelling agent, but from the viewpoint of gelling ability and gelling rate, it is preferably 0.01 to 5%, more preferably 0.05 to 2%, and even more preferably 0.05 to 1%, by mass relative to the total amount of the granule formulation. The content of the gelling agent may be 0.1% or more within the above range.

[0021] The granule preparation of the present invention can be produced by adding a gelling agent to granules containing isoleucine, leucine and valine, which have been produced by a conventionally known method.

[0022] In the present invention, the particle size of isoleucine, leucine, and valine may be adjusted by co-pulverizing the solid raw amino acids of isoleucine, leucine, and valine according to the method described in Japanese Patent No. 3228288. Co-pulverization can be performed by either a method in which isoleucine, leucine, and valine are mixed in advance and then pulverized, or a method in which isoleucine, leucine, and valine are mixed and pulverized at the same time.

[0023] The mixing of solid raw material amino acids is not particularly limited, and examples that can be used include container rotation type mixers such as container type mixers, air agitation type mixers such as fluidized bed type mixers, agitation mixers that use rotation of agitating blades and agitating ribbons, line mixers that perform mixing in a powder transport line, and feeder type mixers that are installed at the raw material supply port of a pulverizer or the like.

[0024] The grinding of the solid raw amino acid may be performed using, but is not limited to, an impact (high-speed rotation) grinder such as a hammer mill or a pin mill, a tumbler (media) grinder such as a ball mill, or a fluid (airflow) grinder such as a jet mill.

[0025] In the production of the granules containing isoleucine, leucine, and valine of the present invention, for example, a high-speed agitation granulator, a fluidized bed granulator, a planetary mixer, a dry-type pressure granulator, a crushing granulator, an extrusion granulator, a tumbling granulator, a spray-drying granulator, or a coating granulator can be used, but is not particularly limited thereto. It is preferable to produce the granules using a high-speed agitation granulator or an extrusion granulator. Examples of extrusion granulators include, but are not limited to, a forward extrusion granulator, a disk pelletizer granulator, a ring die granulator, a basket granulator, an oscillating granulator, and a cylinder granulator.

[0026] When producing granules, known additives that can be used for pharmaceutical purposes and that meet the standards of the Japanese Pharmacopoeia or pharmaceutical additives standards can be blended. The additives are not particularly limited, but examples include additives known as binders, lubricants, colorants, plasticizers, surfactants, sweeteners, flavoring agents, odorants, and fragrances, with binders and / or flavoring agents being preferred. The additives may be used alone or as a mixture of two or more.

[0027] Examples of binders include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, and hydroxypropylmethylcellulose phthalate; starches such as corn starch and wheat starch; synthetic polymers such as polyvinylpyrrolidone (povidone), polyvinyl alcohol, and acrylic acid polymers; and natural polymers such as gum arabic and gelatin. Examples of flavoring agents include, but are not limited to, citric acid, tartaric acid, aspartame, saccharin, saccharin sodium, erythritol, xylitol, mannitol, and stevia. Flavoring agents also include additives known as sweeteners. Examples of odorants and fragrances include, but are not limited to, menthol, lemon flavor, sugarless flavor, sweet flavor, and strawberry oil.

[0028] In the present invention, preferably, a flavoring agent and / or a fragrance is attached to the surface of granules containing isoleucine, leucine, and valine by the method described in Japanese Patent No. 3405342. The particle size of the granules to which the flavoring agent and / or fragrance is attached is not particularly limited as long as the granules can easily maintain a fluidized state in a normal fluidized bed, but is generally 100 to 2000 μm, and preferably about 200 to 1700 μm.

[0029] The fluidization device for adhering the flavoring agent and / or odorant to the granules is not particularly limited, but examples thereof include the fluidized bed drying device "Flow Dryer" manufactured by Freund Corporation, the fluidized bed granulation coating device "Flow Coater" manufactured by Freund Corporation, the "Glatt GPCG" manufactured by Powrex Corporation, the "Marmerizer" manufactured by Dalton Corporation, and the "Multiprocessor" manufactured by Kikusui Seisakusho Co., Ltd.

[0030] In the present invention, a gelling agent is mixed with granules containing isoleucine, leucine, and valine, preferably granules to which a flavoring agent and / or odorant has been attached. In the present invention, it is preferable to add a powder of a gelling agent to granules containing isoleucine, leucine, and valine, preferably granules to which a flavoring agent and / or odorant has been attached, and then mix them. Such mixing methods are not particularly limited as long as they can achieve a substantially uniform mixture, and examples include methods using mixers such as general container-rotating mixers (e.g., V-type, double cone type, rotary rocking type, etc.), fixed container mixers (e.g., ribbon type, conical screw type, etc.), and airflow agitation mixers. Alternatively, a method may be used in which specified amounts of each formulation are added to designated containers using a packaging machine or the like and mixed.

[0031] A granular preparation containing a gelling agent in powder form is obtained by adding the gelling agent to granules containing isoleucine, leucine, and valine and mixing the mixture. The granular preparation of the present invention is composed of granules to which a gelling agent has been added, and such granules are granules as defined in the Japanese Pharmacopoeia (see page 11 for the 17th revision of the Japanese Pharmacopoeia). In the present invention, the particle size of the granular preparation is generally 100 to 2000 μm, and preferably about 200 to 1700 μm.

[0032] In the present invention, particle size means the average particle size of particles, which can be measured by the General Test Method 3.04 "Particle Size Measurement Method" Method 2 "Sieving Method" described in the Japanese Pharmacopoeia, 17th Edition (pp. 95-97). It may also be measured by the General Test Method 6.03 "Test Method for Particle Size of Preparations" described in the Japanese Pharmacopoeia, 17th Edition (pp. 135).

[0033] The granule preparation of the present invention may be a granule preparation obtained by the method for producing a granule preparation of the present invention. The granule preparation of the present invention has an improved feeling when taken, such as an improved bitter taste derived from amino acids and an improved feeling of granules remaining in the mouth.

[0034] The present invention provides a method for improving the swallowing experience of a granule formulation containing isoleucine, leucine, and valine as active ingredients by adding a powdered gelling agent to the formulation. The improvements in swallowing experience include reducing the bitterness derived from amino acids and reducing the residual taste of the granule formulation in the mouth.

[0035] The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto. Those skilled in the art can modify the present invention in various aspects without departing from the spirit of the present invention, and such modifications are also within the scope of the present invention.

[0036] Example 1 A granule preparation was prepared based on the formulation shown in Table 1. To a mixture of L-isoleucine, L-leucine, and L-valine, povidone (Kollidon, 90F), polyvinyl alcohol (partially saponified), tartaric acid, and an aqueous solution of sodium saccharin hydrate were added, and the mixture was granulated using a mixing granulator, sized, and dried to obtain elementary granules. A flavor was spread over the elementary granules, and the granules were sized. Then, polyethylene oxide (average molecular weight: 5,000,000) was added as a powder to prepare a granule preparation.

[0037] Comparative Example 1 A granule preparation was prepared based on the formulation shown in Table 1. Elementary granules were obtained in the same manner as in Example 1. The elementary granules were coated with an aqueous solution of povidone (Kollidon, 90F), and then flavor was spread on them and the particles were sized to prepare a granule preparation.

[0038]

[0039] Using the granule formulations prepared in Example 1 and Comparative Example 1, sensory evaluation was performed using the following indicators: ease of swallowing, difficulty of granules remaining, and weak bitterness (n=9). For ease of swallowing, both granule formulations were compared when taken, and the one that was easier to swallow was selected. For difficulty of granules remaining in the mouth, both granule formulations were compared when taken, and the one that was less likely to remain in the mouth was selected. For weak bitterness, both granule formulations were compared, and the one with the weaker bitterness was selected. The results are shown in Table 2.

[0040]

[0041] The granule formulation of Example 1 was found to be superior to the granule formulation of Comparative Example 1, which is a formulation of Livact-containing granules, in terms of ease of swallowing, less granule residue, and bitterness, and therefore is a granule formulation with an excellent feeling when taken.

[0042] Using the granule preparations prepared in Example 1 and Comparative Example 1, dissolution properties were evaluated by a paddle method using the second dissolution test fluid in the Japanese Pharmacopoeia, 17th Edition (General Test Methods 6.10 "Dissolution Test Method" on pages 141-145). The results are shown in Figures 1 and 2.

[0043] It was confirmed that the granule formulation of Example 1 had lower initial dissolution (5-minute value) than the granule formulation of Comparative Example 1, but after 15 minutes, both formulations showed nearly 100% dissolution. It was thought that the granule formulation of Example 1 also exhibited efficacy similar to that of the Livact-containing granules.

[0044] Examples 2 to 4 Granule preparations were prepared in the same manner as in Example 1, except that the content of polyethylene oxide (average molecular weight: 5,000,000) was adjusted to 0.1%, 1%, or 2% of the total amount of the granule preparation.

[0045] Examples 5 to 7 Granule preparations were prepared in the same manner as in Example 1, except that polyethylene oxides having an average molecular weight of 500,000, 1,000,000 or 2,000,000 were used.

[0046] Using the granule preparations prepared in Examples 1 to 7, a sensory evaluation was carried out using foreign body sensation, bitterness, and ease of swallowing as indicators (n=10). Each indicator was scored as follows: not noticeable: 1 point, barely noticeable: 2 points, somewhat noticeable: 3 points, noticeable: 4 points, and the average score was calculated. The results are shown in Table 3.

[0047]

[0048] The granule formulation of the present invention is considered to have improved swallowing properties compared to the current Livact-containing granule formulation, and therefore has industrial applicability as a pharmaceutical granule formulation.

Claims

1. A granular preparation containing isoleucine, leucine, and valine as active ingredients, the granular preparation containing a gelling agent.

2. The granular preparation according to claim 1, wherein the gelling agent is carboxyvinyl polymer or polyethylene oxide.

3. The granular preparation according to claim 1 or 2, wherein the gelling agent is polyethylene oxide having an average molecular weight of 500,000 or more.

4. The granular preparation according to any one of claims 1 to 3, wherein the gelling agent is added in powder form.

5. The granular preparation according to any one of claims 1 to 4, containing 0.05 to 2% of the gelling agent based on the total amount of the granular preparation.

6. The granular preparation according to any one of claims 1 to 5, containing isoleucine / leucine / valine in a weight ratio of 1 / 1.9 to 2.2 / 1.1 to 1.

3.

7. The granular preparation according to any one of claims 1 to 6, containing 80% or more of isoleucine, leucine, and valine based on the total amount of the granular preparation.

8. The granular preparation according to any one of claims 1 to 7, further containing a binder and / or a flavoring agent.

9. A method for producing a granular preparation containing isoleucine, leucine, and valine as active ingredients, the method comprising adding a gelling agent to granules containing isoleucine, leucine, and valine.

10. The production method according to claim 9, wherein the gelling agent is added in powder form.